News

Money Talks News on MSN1d
Are Your Weight-Loss Drugs Real? Novo Nordisk Sounds Alarm on Knockoffs
One in eight Americans use GLP-1 weight-loss drugs, but are they getting the real thing? Novo Nordisk's dramatic exit from a popular platform reveals the hidden risks of online prescriptions.
Lilly Down More Than 15% in a Year: Time to Buy, Sell or Hold?
LLY has slid 15.7% over the past year, but surging demand for Mounjaro and Zepbound could revive the stock's momentum.
Measles cases In U.S. hit 1,288, highest since disease eliminated in 2000
The number of reported measles cases in the United States has hit 1,288 in the first six months of this year, the most since ...
Novo Nordisk’s Canadian drug patent lapses, opening market for Hims & Her Health
Hims and Hers Health is planning to cash in on Novo Nordisk losing its semaglutide drug exclusivity in Canada. The telehealth ...
Novo Nordisk Receives Boost on $2.34B Italian Factory
Novo Nordisk A/S (NYSE:NVO) is one of the 10 best defensive stocks to buy in a volatile market. On July 7, the company ...
Copper now costs way more in the U.S. than elsewhere. This could hit its economy hard
As U.S. prices remain elevated despite larger-than-usual inventories, the gap in U.S. Comex futures over those on the LME has fluctuated between $500 and $1,500 since Trump announced a probe into ...
2 S&P 500 Dividend Stocks That Could Climb 17% or More, According to Wall Street
Stocks that pay dividends tend to outperform ones that don't. Consensus price targets for Novo Nordisk suggest the stock can ...
Wegovy and Zepbound prices fall, but access to the obesity drugs still isn’t guaranteed
Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...